0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > All Other Proteins > Siglec-3 > CD3-H82F3

Biotinylated Human Siglec-3 / CD33 Protein, Fc,Avitag™ (MALS verified)

  • Synonym
    CD33,SIGLEC3,gp67
  • Source
    Biotinylated Human Siglec-3,Fc,Avitag (CD3-H82F3) is expressed from human 293 cells (HEK293). It contains AA Asp 18 - His 259 (Accession # AAH28152.1).
    Predicted N-terminus: Asp 18
  • Molecular Characterization
    Online(Asp 18 - His 259) AAH28152.1

    This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™).

    The protein has a calculated MW of 54.9 kDa. The protein migrates as 70-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Biotinylation
    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
  • Biotin:Protein Ratio
    The biotin to protein ratio is 0.5-1 as determined by the HABA assay.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by reduced SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Biotinylated Human Siglec-3,Fc,Avitag (Cat. No. CD3-H82F3) SDS-PAGE gel

Biotinylated Human Siglec-3,Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS
Biotinylated Human Siglec-3,Fc,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human Siglec-3,Fc,Avitag (Cat. No. CD3-H82F3) was more than 90% and the molecular weight of this protein is around 155-185 kDa verified by SEC-MALS.

Bioactivity-ELISA
Biotinylated Human Siglec-3,Fc,AvitagBiotinylated Human Siglec-3,Fc,Avitag (Cat. No. CD3-H82F3) ELISA bioactivity

Immobilized Biotinylated Human Siglec-3,Fc,Avitag (Cat. No. CD3-H82F3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-Siglec-3 Antibody, Human IgG1 with a linear range of 0.2-2 ng/mL (QC tested).

  • Background
    Myeloid cell surface antigen CD33 is also known as SIGLEC3, Siglecs (sialic acid binding Ig­like lectins) and GP67, is a single-pass type I membrane protein which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. Human CD33 / Siglec-3 cDNA encodes a 364 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-­terminal Ig-­like V­-type domain, one Ig­-like C2-­type domains, a transmembrane region and a cytoplasmic tail. CD33 / Siglec-3 usually considered myeloid-specific, but it can also be found on some lymphoid cells. In the immune response, CD33 / Siglec-3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. CD33 / Siglec-3 induces apoptosis in acute myeloid leukemia.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $350.00

Price(USD) : $1380.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:1 Details
  • Number of Drugs in Clinical Trials:20 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop